E-Mail
WASHINGTON - Pancreatic cancer, one of the most lethal of all cancers, is capable of evading attacks by immune cells by changing its microenvironment so that the immune cells suppress, rather than support, an attack on the tumor. The scientists also found that that some of the mediators of this suppressive response, including a protein called STAT1, represent potential therapeutic targets that could be used to reverse this evasion and point to possible treatment opportunities.
The finding appears January 28, 2021, in
Cancer Immunology Research. This is the first demonstration that an immune attack induces pancreatic cancer-derived immune suppression, offering a new approach to immunotherapy for this deadly cancer, noted Louis M. Weiner, M.D., director of Georgetown Lombardi and the Principal Investigator of this study.
oncology drug discovery services market 2020 by Key Driving Factor, Dazzling Growth, Vital Players, Regions, Segments, Type, Treatment Type, & Outlook to 2023
Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.
The research study presented here is an intelligent take on oncology drug discovery services market
by MRFR that explains important aspects such as competition, segmentation, and regional growth in great detail Drug Discovery Services Market Insight Drug discovery services means outsourcing the development process of any new drug or medicine. These kinds of services reduce the costs as well as the time taken during drug discovery. The commonly used methods for drug discoveries include drug metabolites, serendipity, molecular manipulation, molecular designing, and random screening.